


PHARMACEUTICAL 2020


Regulus Therapeutics Inc. Rank 173 of 362













The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is -167%, being 136% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	40,407
Cost of Goods Sold	0
Intangible Assets	266
Liabilities, Current	21,598
Liabilities, Non-Current	468
Other Assets	487
Other Compr. Net Income	0
Other Expenses	2,132
Other Liabilities	0
Other Net Income	0
Property and Equipment	921
Research and Development	12,349
Revenues	7,206
Selling, General and Administrative Expense	11,317

Output Variable	Value in 1000 USD
Assets	42,081
Liabilities	22,066
Expenses	25,798
Stockholders Equity	20,015
Net Income	-18,592
Comprehensive Net Income	-18,592
Economic Capital Ratio	-167%

